Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3

Archives of Pharmacal Research

Volumn 33, Issue 7, 2010, Pages 1127-1132

  Le, Tuong Vy Thi ^a   Seo, Youngcheol ^a   Ryu, Chun Jeih ^b   Lee, Hye Ran ^c   Park, Hyun Ju ^a  

^a Sungkyunkwan University   (South Korea)

^b Sejong University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bax; Cisplatin resistance; Human gastric cancer; p21; p27; p53

Indexed keywords

CISPLATIN; PROTEIN BAX; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STOMACH CANCER; WESTERN BLOTTING;

CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; STOMACH NEOPLASMS; UP-REGULATION;

EID: 77955380286     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-0720-5     Document Type: Article

References (33)

1. J. M. Bae Y. J. Won K. W. Jung K. A. Suh D. H. Ahn J. G. Park 2001 Annual Report of the Central Cancer Registry in Korea-1999: Based on Registered Data from 128 Hospitals Cancer Res. Treat. 33 367 372
2. D. Banerjee P. Mayer-Kuckuk G. Capiaux T. Budak-Alpdogan R. Gorlick J. R. Bertino 2002 Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase Biochim. Biophys. Acta 1587 164 173 1:CAS:528:DC%2BD38XkslKjur4%3D 12084458
3. R. Brown G. L. Hirst W. M. Gallagher A. J. McIlwrath G. P. Margison A. G. Van der Zee D. A. Anthoney 1997 hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents Oncogene 15 45 52 10.1038/sj.onc.1201167 1:CAS:528:DyaK2sXkslygsbo%3D 9233776
4. F. Bunz P. M. Hwang C. Torrance T. Waldman Y. Zhang L. Dillehay J. Williams C. Lengauer K. W. Kinzler B. Vogelstein 1999 Disruption of p53 in human cancer cells alters the responses to therapeutic agents J. Clin. Invest. 104 263 269 10.1172/JCI6863 1:CAS:528:DyaK1MXkvFagsbc%3D 10430607
5. D. Chatterjee C. J. Liu D. Northey B. A. Teicher 1995 Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors Cancer Chemother. Pharmacol. 35 423 431 10.1007/s002800050257 1:CAS:528:DyaK2MXkslGitbo%3D 7850925
6. W. Dempke W. Voigt A. Grothey B. T. Hill H. Schmoll 2000 Cisplatin resistance and oncogenes: a review Anticancer Drugs 11 225 236 10.1097/00001813-200004000-00001 1:CAS:528:DC%2BD3cXkvVygu7k%3D 10898536 (Pubitemid 30416950)
7. C. Denicourt S. F. Dowdy 2004 Cip/Kip proteins: more than just CDKs inhibitors Genes Dev. 18 851 855 10.1101/gad.1205304 1:CAS:528: DC%2BD2cXjsFKks7k%3D 15107401 (Pubitemid 38529654)
8. M. Dimanche-Boitrel O. Micheau A. Hammann M. Haugg B. Eymin B. Chauffert E. Solary 1998 Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of colon carcinoma HT29 cells Int. J. Cancer 77 796 802 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2- Z 1:STN:280:DyaK1czltFKjsw%3D%3D 9688315 (Pubitemid 28341399)
9. A. G. Eliopoulos D. J. Kerr J. Herod L. Hodgkins S. Krajewski J. C. Reed L. S. Young 1995 The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 Oncogene 11 1217 1228 1:CAS:528:DyaK2MXptVWntr8%3D 7478541
10. Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells Oncogene 18 1411 1418 10.1038/sj.onc.1202437 1:CAS:528:DyaK1MXhs1yht7s%3D 10050878
11. D. Fink S. Nebel S. Aebi H. Zheng B. Cenni A. Nehme R. D. Christen S. B. Howell 1996 The role of DNA mismatch repair in platinum drug resistance Cancer Res. 56 4881 4886 1:CAS:528:DyaK28XmsFygsbg%3D 8895738 (Pubitemid 26374423)
12. D. Fink H. Zheng S. Nebel P. S. Norris S. Aebi T. P. Lin A. Nehme R. D. Christen M. Haas C. L. MacLeod S. B. Howell 1997 In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Res. 57 1841 1845 1:CAS:528:DyaK2sXjtlGlt78%3D 9157971
13. M. Fritsche C. Haessler G. Brandner 1993 Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents Oncogene 8 307 318 1:CAS:528:DyaK3sXhtl2nsro%3D 8426740
14. M. M. Gottesman 2002 Mechanisms of cancer drug resistance Annu. Rev. Med. 53 615 627 10.1146/annurev.med.53.082901.103929 1:CAS:528:DC%2BD38Xitl2mtLo%3D 11818492 (Pubitemid 34177898)
15. A. S. Juvekar M. K. Adwankar H. B. Tongaonkar 2000 Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer Cancer Biother. Radiopharm. 15 295 300 10.1089/108497800414392 1:CAS:528:DC%2BD3cXlvVylurw%3D 10941537
16. M. Kartalou J. M. Essigmann 2001 Mechanisms of resistance to cisplatin Mutat. Res. 478 23 43 1:CAS:528:DC%2BD3MXkt1yjurk%3D 11406167
17. M. B. Kastan O. Onyekwere D. Sidransky B. Vogelstein R. W. Craig 1991 Participation of p53 protein in the cellular response to DNA damage Cancer Res. 51 6304 6311 1:CAS:528:DyaK38XhvFSltg%3D%3D 1933891
18. J. R. Kelley J. M. Duggan 2003 Gastric cancer epidemiology and risk factors J. Clin. Epidemiol. 56 1 9 10.1016/S0895-4356(02)00534-6 12589864 (Pubitemid 36183309)
19. S. J. Kuerbitz B. S. Plunkett W. V. Walsh M. B. Kastan 1992 Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc. Natl. Acad. Sci. U. S. A. 89 7491 7495 10.1073/pnas.89.16.7491 1:CAS:528:DyaK38Xls1Kkt7c%3D 1323840
20. A. K. Larsen A. E. Escargueil A. Skladanowski 2000 Resistance mechanisms associated with altered intracellular distribution of anticancer agents Pharmacol. Ther. 85 217 229 10.1016/S0163-7258(99)00073-X 1:CAS:528: DC%2BD3cXitVWjs7Y%3D 10739876 (Pubitemid 30160791)
21. Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade Mol. Cell 1 553 563 10.1016/S1097-2765(00)80055-6 1:CAS:528:DyaK1cXit1Gisb4%3D 9660939
22. X. Lin K. Ramamurthi M. Mishima A. Kondo S. B. Howell 2000 p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide Mol. Pharmacol. 58 1222 1229 1:CAS:528:DC%2BD3cXovFeru7s%3D 11093757
23. S. Q. Liu J. P. Yu H. G. Yu P. Lv H. Chen 2006 Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells Dig. Liver Dis. 38 310 318 10.1016/j.dld.2006.01.012 1:CAS:528:DC%2BD28XmtlKgurk%3D 16527552 (Pubitemid 44356199)
24. C. Marth M. Widschwendter J. Kaern N. P. Jorgensen G. Windbichler A. G. Zeimet C. Trope G. Daxenbichler 1997 Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells Br. J. Cancer 76 1328 1332 1:CAS:528:DyaK2sXns1OmsLY%3D 9374379
25. J. A. Mello S. Acharya R. Fishel J. M. Essigmann 1996 The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin Chem. Biol. 3 579 589 10.1016/S1074-5521(96)90149-0 1:CAS:528: DyaK28XkvFWgu7c%3D 8807890 (Pubitemid 26324171)
26. H. Miyake N. Hanada H. Nakamura S. Kagawa T. Fujiwara I. Hara H. Eto K. Gohji S. Arakawa S. Kamidono H. Saya 1998 Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer Oncogene 16 933 943 10.1038/sj.onc.1201602 1:CAS:528: DyaK1cXhs1yjtbk%3D 9484785 (Pubitemid 28102597)
27. N. Olashaw W. J. Pledger 2002 Paradigms of growth control: relation to Cdk activation Sci. STKE 2002 re7 10.1126/stke.2002.134.re7 12034920
28. J. Philipp-Staheli S. R. Payne C. J. Kemp 2001 Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer Exp. Cell Res. 264 148 168 10.1006/excr.2000.5143 1:CAS:528:DC%2BD3MXhsFOhurY%3D 11237531 (Pubitemid 32989089)
29. A. H. Reitmair R. Risley R. G. Bristow T. Wilson A. Ganesh A. Jang J. Peacock S. Benchimol R. P. Hill T. W. Mak R. Fishel M. Meuth 1997 Mutator phenotype in Msh2-deficient murine embryonic fibroblasts Cancer Res. 57 3765 3771 1:CAS:528:DyaK2sXlvFent7c%3D 9288785
30. C. J. Sherr J. M. Roberts 1999 CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev. 13 1501 1512 10.1101/gad.13.12. 1501 1:CAS:528:DyaK1MXktlOhsLs%3D 10385618
31. A. Vaisman M. Varchenko A. Umar T. A. Kunkel J. I. Risinger J. C. Barrett T. C. Hamilton S. G. Chaney 1998 The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts Cancer Res. 58 3579 3585 1:CAS:528:DyaK1cXlsFajtrY%3D 9721864
32. Q. Yang T. Sakurai G. Yoshimura Y. Takashi T. Suzuma T. Tamaki T. Umemura Y. Nakamura M. Nakamura H. Utsunomiya I. Mori K. Kakudo 2000 Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C Anticancer Res. 20 4319 4322 1:CAS:528: DC%2BD3MXhtVejsrs%3D 11205265
33. S. S. Yoon K. S. Ahn S. H. Kim Y. M. Shim J. Kim 2001 In vitro establishment of cis-diammine-dichloroplatinum (II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype Lung Cancer 33 221 228 10.1016/S0169-5002(01)00205-7 1:STN:280:DC%2BD3MrgtF2ntQ%3D%3D 11551417 (Pubitemid 32707903)